Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23275100 | 0.92 | PKM (0.40) | POLBL3MBTL1MEN1KMT2APKM | |
| SCHEMBL16985270 | 0.92 | PKM (0.37) | POLBL3MBTL1MEN1KMT2AGSK3A | |
| SCHEMBL19716115 | 0.87 | POLB (0.39) | POLBL3MBTL1MEN1KMT2APKM | |
| SCHEMBL19716126 | 0.87 | POLB (0.39) | POLBL3MBTL1MEN1KMT2APKM | |
| SCHEMBL26121604 | 0.86 | PKM (0.38) | POLBL3MBTL1MEN1KMT2APKM | |
| SCHEMBL20555375 | 0.84 | PDE1C (0.42) | POLBALDH1A1CYP2C9MAPT | |
| SCHEMBL17610463 | 0.83 | L3MBTL1 (0.40) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL17610460 | 0.83 | L3MBTL1 (0.40) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL15995596 | 0.82 | ALOX15 (0.50) | POLBL3MBTL1MEN1KMT2APKM | |
| SCHEMBL30996604 | 0.82 | PKM (0.36) | POLBL3MBTL1MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| CN-105940004-B | Compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2018-02-02 | — | — | CN | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | POLB 1043/4885L3MBTL1 304/4885MEN1 4432/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | POLB 1065/4885L3MBTL1 491/4885MEN1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.